320 related articles for article (PubMed ID: 35618837)
1. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
Zeng AGX; Bansal S; Jin L; Mitchell A; Chen WC; Abbas HA; Chan-Seng-Yue M; Voisin V; van Galen P; Tierens A; Cheok M; Preudhomme C; Dombret H; Daver N; Futreal PA; Minden MD; Kennedy JA; Wang JCY; Dick JE
Nat Med; 2022 Jun; 28(6):1212-1223. PubMed ID: 35618837
[TBL] [Abstract][Full Text] [Related]
2. A single-cell survey of cellular hierarchy in acute myeloid leukemia.
Wu J; Xiao Y; Sun J; Sun H; Chen H; Zhu Y; Fu H; Yu C; E W; Lai S; Ma L; Li J; Fei L; Jiang M; Wang J; Ye F; Wang R; Zhou Z; Zhang G; Zhang T; Ding Q; Wang Z; Hao S; Liu L; Zheng W; He J; Huang W; Wang Y; Xie J; Li T; Cheng T; Han X; Huang H; Guo G
J Hematol Oncol; 2020 Sep; 13(1):128. PubMed ID: 32977829
[TBL] [Abstract][Full Text] [Related]
3. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.
Karantanos T; Jones RJ
Adv Exp Med Biol; 2019; 1139():153-169. PubMed ID: 31134500
[TBL] [Abstract][Full Text] [Related]
4. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance.
Fan H; Wang F; Zeng A; Murison A; Tomczak K; Hao D; Jelloul FZ; Wang B; Barrodia P; Liang S; Chen K; Wang L; Zhao Z; Rai K; Jain AK; Dick J; Daver N; Futreal A; Abbas HA
Commun Biol; 2023 Jul; 6(1):765. PubMed ID: 37479893
[TBL] [Abstract][Full Text] [Related]
5. A deconvolution method and its application in analyzing the cellular fractions in acute myeloid leukemia samples.
Li H; Sharma A; Ming W; Sun X; Liu H
BMC Genomics; 2020 Sep; 21(1):652. PubMed ID: 32967610
[TBL] [Abstract][Full Text] [Related]
6. A longitudinal single-cell atlas of treatment response in pediatric AML.
Lambo S; Trinh DL; Ries RE; Jin D; Setiadi A; Ng M; Leblanc VG; Loken MR; Brodersen LE; Dai F; Pardo LM; Ma X; Vercauteren SM; Meshinchi S; Marra MA
Cancer Cell; 2023 Dec; 41(12):2117-2135.e12. PubMed ID: 37977148
[TBL] [Abstract][Full Text] [Related]
7. Cellular hierarchies predict drug response in acute myeloid leukemia.
Raffel S; Velten L; Haas S
Cancer Cell; 2022 Sep; 40(9):917-919. PubMed ID: 36055227
[TBL] [Abstract][Full Text] [Related]
8. Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.
Chen C; Wang L; Li L; Wang A; Huang T; Hu J; Zhao M; Liu F; Qi S; Hu C; Wang W; Liu J; Ge J; Xia R; Wang W; Liu Q
Exp Cell Res; 2020 Aug; 393(1):112054. PubMed ID: 32376287
[TBL] [Abstract][Full Text] [Related]
9. Molecular biomarkers in acute myeloid leukemia.
Prada-Arismendy J; Arroyave JC; Röthlisberger S
Blood Rev; 2017 Jan; 31(1):63-76. PubMed ID: 27639498
[TBL] [Abstract][Full Text] [Related]
10. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
Lam SS; He AB; Leung AY
Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
[TBL] [Abstract][Full Text] [Related]
12. Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia.
Shingai Y; Yokota T; Okuzaki D; Sudo T; Ishibashi T; Doi Y; Ueda T; Ozawa T; Nakai R; Tanimura A; Ichii M; Shibayama H; Kanakura Y; Hosen N
Stem Cells; 2021 Jun; 39(6):723-736. PubMed ID: 33539590
[TBL] [Abstract][Full Text] [Related]
13. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
15. The Evolving AML Genomic Landscape: Therapeutic Implications.
Horibata S; Alyateem G; DeStefano CB; Gottesman MM
Curr Cancer Drug Targets; 2020; 20(7):532-544. PubMed ID: 32329691
[TBL] [Abstract][Full Text] [Related]
16. New drugs for acute myeloid leukemia inspired by genomics and when to use them.
Pollyea DA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):45-50. PubMed ID: 30504290
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
Stubbins RJ; Maksakova IA; Sanford DS; Rouhi A; Kuchenbauer F
Leuk Lymphoma; 2021 Oct; 62(10):2331-2341. PubMed ID: 34060970
[TBL] [Abstract][Full Text] [Related]
18. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
Wang A; Zhong H
Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
[TBL] [Abstract][Full Text] [Related]
19. Novel Treatment Paradigms in Acute Myeloid Leukemia.
Khanal N; Upadhyay Banskota S; Bhatt VR
Clin Pharmacol Ther; 2020 Sep; 108(3):506-514. PubMed ID: 32572947
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Burd A; Levine RL; Ruppert AS; Mims AS; Borate U; Stein EM; Patel P; Baer MR; Stock W; Deininger M; Blum W; Schiller G; Olin R; Litzow M; Foran J; Lin TL; Ball B; Boyiadzis M; Traer E; Odenike O; Arellano M; Walker A; Duong VH; Kovacsovics T; Collins R; Shoben AB; Heerema NA; Foster MC; Vergilio JA; Brennan T; Vietz C; Severson E; Miller M; Rosenberg L; Marcus S; Yocum A; Chen T; Stefanos M; Druker B; Byrd JC
Nat Med; 2020 Dec; 26(12):1852-1858. PubMed ID: 33106665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
